POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative

CVM-1118 (foslinanib) is a phosphoric ester compound selected from 2-phenyl-4-quinolone derivatives. The NCI 60 cancer panel screening showed CVM-1125, the major active metabolite of CVM-1118, to exhibit growth inhibitory and cytotoxic effects at nanomolar range. CVM-1118 possesses multiple bioactivities, including inducing cellular apoptosis, cell cycle arrest at G2/M, as well as inhibiting vasculogenic mimicry (VM) formation. The TNF receptor associated protein 1 (TRAP1) was identified as the binding target of CVM-1125 using nematic protein organization technique (NPOT) interactome analysis. Further studies demonstrated CVM-1125 reduced the protein level of TRAP1 and impeded its downstream signaling by reduction of cellular succinate levels and destabilization of HIF-1α. The pharmacogenomic biomarkers associated with CVM-1118 were also examined by Whole Genome CRISPR Knock-Out Screening. Two hits (STK11 and NF2) were confirmed with higher sensitivity to the drug in cell knock-down experiments. Biological assays indicate that the mechanism of action of CVM-1118 is via targeting TRAP1 to induce mitochondrial apoptosis, suppress tumor cell growth, and inhibit vasculogenic mimicry formation. Most importantly, the loss-of-function mutations of STK11 and NF2 are potential biomarkers of CVM-1118 which can be applied in the selection of cancer patients for CVM-1118 treatment. CVM-1118 is currently in its Phase 2a clinical development.

Full article: Developing our knowledge of the quinolone scaffold and its value to anticancer drug design

HSP 75 Antibody (TR1) SCBT - Santa Cruz Biotechnology

LKB1-deficient tumor cells display enhanced glycolytic and TCA cycle

POR Three-dimensional analysis of perineural invasion in extrahepatic cholangiocarcinoma using tissue clearing

A complex-level interaction network. a, a fragment of our Complex- Net

Effect of evodiamine on ABCA1 transcription and the degradation rate of

TRAP1 Knockdown Inhibits In Vitro and In Vivo Neoplastic Transformation

POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1

Molecules, Free Full-Text

Foslinanib, C16H13FNO6P

Molecules, Free Full-Text

HIF-1α Antibody Cell Signaling Technology